• 1\. Patients must be ≥ 1 years of age

• 2\. Patients must demonstrate expression of at least one of the following HLA alleles by HLA genotyping (conducted at CHOP) to be eligible.

∙ HLA-A\*24:02 HLA-A\*24:03 HLA-A\*24:04 HLA-A\*24:07 HLA-A\*24:124 HLA-A\*24:143 HLA-A\*24:17 HLA-A\*24:242 HLA-A\*24:305 HLA-A\*24:314 HLA-A\*24:33 HLA-A\*24:353 HLA-A\*24:41 HLA-A\*24:51 HLA-A\*24:63 HLA-A\*24:87 HLA-A\*24:92 HLA-A\*23:01 HLA-A\*23:17 HLA-A\*23:25 HLA-A\*23:39

∙ 3\. Patients must have high-risk neuroblastoma according to COG risk classification at the time of study enrollment. Patients who were initially considered low- or intermediate-risk, but then reclassified as high-risk are also eligible.

∙ 4\. Patients must have a previously histologically confirmed diagnosis of neuroblastoma That is recurrent/relapsed or refractory/persistent according to INRC AND For which standard curative measures do not exist or are no longer effective. Patients at first relapse are eligible as no known curative therapies exist for relapsed high-risk neuroblastoma.

∙ 5\. Patients must have evaluable or measurable disease at enrollment. 5. The patient must have experienced at least one of the following:

∙ a. New disease site documented on at least one of the following: i. 123I-meta-iodobenzylguanidine (MIBG) or 18F-mFBG (meta-fluorobenzylguanidine) scan; OR ii. CT/MRI; OR iii. FDG or Ga-68 Dotatate PET (in patients known to have MIBG non-avid tumor) and MRI findings consistent with tumor (i.e., bone lesions), OR iv. Biopsy confirmed neuroblastoma for any new or progressing lesion. b. Greater than 20% increase in a least one dimension of soft tissue mass documented by CT/MRI and a minimum absolute increase of 5 mm in longest dimension in existing lesion(s). Previously irradiated lesions may be included.

∙ c. Bone marrow biopsy shows progressive disease according to the revised INRC.61 d. Stable persistent disease, such that response at the completion of upfront therapy or salvage therapy is less than partial response AND has a biopsy of at least one site showing viable neuroblastoma.

∙ e. Responding persistent disease, defined as at least a partial response to frontline therapy (i.e., at least a partial response to frontline therapy but still has residual disease by MIBG scan, CT/MRI, or bone marrow aspirations/biopsies). Patients in this category are required to have histologic confirmation of viable neuroblastoma from at least one residual site (tumor seen on routine bone marrow morphology is sufficient)

∙ 6\. Patients must have a Lansky (≤ 16 years) or Karnofsky (\> 16 years) score of ≥ 60.

∙ 7\. Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age: Age Male Female 12 months to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1.0 1.0 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4

• 16 years 1.7 1.4

• 8\. Liver Function as follows:

⁃ Total bilirubin ≤ 1.5 x ULN (exception: total bilirubin ≤ 3 ULN for patients with Gilbert's Disease or liver metastases).

⁃ Alanine aminotransferase (ALT) ≤ 3.0 ULN (exception: ALT ≤ 5 x ULN for patients with liver metastases).

⁃ Aspartate aminotransferase (AST) ≤ 3.0 ULN (exception: ALT ≤ 5 x ULN for patients with liver metastases).

‣ 9\. Pulmonary Function as follows:

• a. Patients need to have a baseline pulse oximetry of at least 92% on room air and DLCO ≥ 60% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator.

• 8\. Cardiac Function as follows:

• a. Left ventricular shortening fraction (LVSF) ≥28% or ejection fraction (LVEF) ≥ 50% confirmed by Echo, or adequate ventricular function documented by a scan or a cardiologist.

• 10\. Patients of child-bearing potential ( patients who have reached menarche and have not experienced treatment-related premature ovarian failure) must have a negative serum pregnancy test performed at the time of screening It is recommended that all patients of reproductive potential use at least one medically acceptable form of contraception for at least 1 year after their last infusion of PHOX2B PC-CAR T cells. Investigators shall counsel patients on the importance of pregnancy prevention and the implications of an unexpected pregnancy.